Home List your patent My account Help Support us
UV-A, UV-B, UV-C & HEV Blocking Contact Lenses
[Category : - HEALTH]
[Viewed 887 times]
special filter system, that is capable of blocking UV-A (315-380 nanometers), UV-B (280-315
nanometers), UV-C (100-280 nanometers) & HEV light (380-500 nanometers). The UV-A, UV-B, UV-C
& HEV Blocking Contact Lenses will be made of polymethyl methacrylate (PMMA). The aim of these
contact lenses is, that they can protect the human eye lens and the retina from the radiation that’s is
emitted by the sun, LCD-screens and LED- screens. The purpose of these lens is to give additional
protection to the human eye. The ‚UVA-,UVB-,UVC- and HEV Blocking Contact Lenses‘’s mechanism
works through absorbing the visual spectrum of UVA-(315-380nm), UVB-(280-315nm),
UVC(100-280nm) radiation. Unfiltered can this radiation cause a state decomposition and
degeneration of retinal cells. Cataract disease origins by an interaction of lens opacification and
presbyopia. Lens opacification mainly gets caused by the high exposure of radiation (of daylight of
LCD-light etc.) the human eye (mainly the human lenses) absorbs. The level of opacification
increases by age. The regular treatment by now mainly is surgical, which means that the nation
receives artificial lenses. Mr. Kingreen’s invented, developed and patented contact lenses could
prevent the development or increasement of such diseases - these lenses could lift patients health-
related quality of life. The even wider field of usage for the ‚UVA-,UVB-,UVC- and HEV Blocking
Contact Lenses‘ is the preventive and accompanying treatment of Macular Degeneration. Macular
Degeneration is one of the most common eye-diseases in Europe and North America. There are two
versions of Macular Degeneration, 1.) the ‚dry‘ (A)MD and 2.) the ‚wet‘ (A)MD, the difference
between these two is, that the second one has caused retinal degeneration processes, which often
conjunctures with a retinal lipid-oxidation. The result out of this process is the process degenerative
cell-reconstruction, which means that the retina produces new non functions cells, that often even
contain liquid. The final state of that degenerative process is the decreasement of the visual acuity
and the establishment of visual dysmorphia. Patients suffering from dysmorphia cannot see lines
straight anymore, the lines will be bend or even cut off. The visual acuity of healthy people lies
between 90-130 per cent, MD affected patients oftenly do not reach a visual acuity of 20 per cent on
the Snellen chart. In the advanced stage of the disease many patients sustain a central loss of their
visual field. That area increases - till the state of total blindness. The final stadium of the Macular
Degeneration is called ‚Kuhnt-Junius-disease‘. There are more than 10 million patients (mainly
women) affected with the (A)MD, only in Europe. The conservative treatment of MD diseases is
managed by intraocular injections of therapeutic liquids. This treatment has a positive response in
the vast majority of cases, but sometimes it is ineffective or even counterproductively. For example
in cases of Myopic Macular Degeneration or Juvenile Macular Degeneration. The ‚UVA-,UVB-,UVC-
and HEV Blocking Contact Lenses‘, invented, developed and patented by Mr. Kingreen, could
become a significant preventive and accompanying treatment of Age related Macular Degeneration,
Myopic Macular Degeneration, Juvenile Macular Degeneration and the Cataract disease. For it could
support the auto-regenerative process of the retina (in cases such as JMD) and for it would slow
down the process of lipid-oxidation. Website’s domain: myvisionlenses.co.uk E-mail:
[Use the button below to contact me]
Financial information
The current value of the patent is within the mid-eight figures.
Patent publications:No publication
Asking price:
Above 1 million USD
Above 1 million USD
Great invention[ Home | List a patent | Manage your account | F.A.Q.|Terms of use | Contact us]
Copyright PatentAuction.com 2004-2017
Page created at 2024-04-25 18:01:11, Patent Auction Time.